Marijuana and the Cannabinoids Edited by Mahmoud A. ElSohly, PhD, Humana Press, Totowa, New Jersey, USA, 2007 www.humanapress.com 1. Cannabinoids. I. ElSohly, Mahmoud A. II. Series. [DNLM: 1. Cannabinoids. 2. Cannabis. QV 77.7 M33515 2006] QP801.C27M355 2006 615'.7827--dc22 333 pages, Preface Although primarily used today as one of the most prevalent illicit leisure drugs, the use of Cannabis sativa L., commonly referred to as marijuana, for medicinal purposes has been reported for more than 5000 years. Marijuana use has been shown to create numerous health problems, and, consequently, the expanding use beyond medical purposes into recreational use (abuse) resulted in control of the drug through international treaties. Much research has been [...]
Lire la suiteLes cannabinoïdes dans l’Autisme : Dr Christian Sueur GRECC (Groupe de Recherches et D’Etudes Cliniques sur les Cannabinoïdes) Version actualisée juin 2019 L’autisme est une pathologie, ou plutôt un trouble majeur du développement psycho-neuro-développemental, à l’étiologie complexe et multifactorielle ; rentrent vraisemblablement en interaction, pour produire un trouble du spectre autistique, aussi bien des facteurs psychologique interactionnels précoces, qu’un terrain de fragilité ou de prédisposition génétique, à l’origine d’anomalies neurophysiologiques du développement de la connectique neuronale. Depuis près d’une vingtaine d’année, les cannabinoïdes représente progressivement une nouvelle voie d’approche thérapeutique des autismes les plus sévères. Certains parents, surtout aux USA[1], ont adopté depuis le début [...]
Lire la suiteWHO Expert Committee on Drug Dependence. Critical Review Cannabis and cannabis resin © World Health Organization 2018 Cannabis and cannabis resin Section 1: Chemistry 1. Substance identification ............................................................................................... 4 1.1 International Nonproprietary Name (INN) .............................................................................................. 4 1.2 Chemical Abstract Service (CAS) registry number ................................................................................... 4 1.3 Other chemical names ............................................................................................................................ 4 1.4 Trade names ........................................................................................................................................... 4 Cannabis 1.4.1 plant .................................................................................................................................. 4 1.4.2 Cannabis resin .................................................................................................................................. 5 1.5 Street names ........................................................................................................................................... 5 1.5.1 Cannabis plant .................................................................................................................................. 5 1.5.2 Cannabis resin .................................................................................................................................. 5 1.6 Physical appearance ............................................................................................................................... 6 1.6.1 Cannabis plant .................................................................................................................................. 6 1.6.2 Cannabis resin .................................................................................................................................. 6 1.7 WHO review history ................................................................................................................................ 7 2. Chemistry ..................................................................................................................... 8 2.1 Name ...................................................................................................................................................... 8 2.2 Chemical name ....................................................................................................................................... 8 2.2.1 IUPAC name: ..................................................................................................................................... 8 2.2.2 CA index [...]
Lire la suiteUsage médical du cannabis et des cannabinoïdes Questions et réponses à l’intention des décideurs politiques Observatoire européen des drogues et des toxicomanies (2019), Office des publications de l’Union européenne, Luxembourg Décembre 2018 PDF ISBN 978-92-9497-406-8 doi:10.2810/25727 TD-06-18-186-FR-N Table des matières : 5 Introduction 6 Quels sont les sujets abordés dans ce rapport? 7 Qu’entend-on par usage médical de cannabis et de cannabinoïdes? 11 PARTIE 1 Quelles données scientifiques attestent-elles d’un usage médical du cannabis et des cannabinoïdes? 11 Comment évaluer l’efficacité des médicaments? 12 Quels sont les données scientifiques récentes de l’efficacité du cannabis et des cannabinoïdes en tant que médicaments? 15 Quels sont les risques pour la santé associés à l’usage médical du [...]
Lire la suiteEpigenetic Effects of Cannabis Exposure Henrietta Szutorisz and Yasmin L. Hurd Biological Psychiatry, 2016, 79, 7, 586–594. doi:10.1016/j.biopsych.2015.09.014. Abstract The past decade has witnessed a number of societal and political changes that have raised critical questions about the long-term impact of marijuana (Cannabis sativa) that are especially important given the prevalence of its abuse and that potential long-term effects still largely lack scientific data. Disturbances of the epigenome have generally been hypothesized as the molecular machinery underlying the persistent, often tissue-specific transcriptional and behavioral effects of cannabinoids that have been observed within one’s lifetime and even into the subsequent generation. Here, we provide an overview [...]
Lire la suiteIntroduction to Recent Advances in Cannabinoid Research Robert B. Laprairie and Will Costain © 2016 The Author(s). Licensee InTechOpen. This chapter is distributed under the terms of the Creative Commons; Attribution License (http://creativecommons.org/licenses/by/3.0), Abstract On October 17, 2018, Canada became the first G20 nation to legalize the use of Cannabis sativa for both medicinal and recreational purposes. This change in legislation and end of prohibition are indicative of a larger global movement to understand Cannabis—and the bioactive chemicals present within Cannabis known as the cannabinoids—for its potential biomedical uses, harms, and economic values. Currently, interest in Cannabis and cannabinoid research is surging as the many [...]
Lire la suiteCannabis à usage médical : la France saura-t-elle combler son retard ? Bertrand Lebeau Leibovici Médecin addictologue Membre fondateur du GRECC Juin 2019 Agnès Buzin réussira-t-elle là où Bernard Kouchner puis Marisole Touraine ont échoué ? En queue de peloton européen sur la question de l’accès au cannabis à usage thérapeutique, la France, reconnait l’actuelle ministre de la Santé, a pris du « retard ». Pour le rattraper, elle a demandé à l’Agence Nationale de Sécurité du Médicament (ANSM) de créer un Comité Scientifique Spécialisé Temporaire (CSST) présidé par le professeur Nicolas Authier, qui dirige aussi la Commission des Stupéfiants et Psychotropes, dans le cadre de l’ANSM. L’enfant chéri de l’Agence a [...]
Lire la suiteMarijuana and fertility Sara Ilnitsky MD, Stan Van Uum MD Canadian Medical Association Journal, 2019 June 10, 191, 23, E638. doi : 10.1503/cmaj.181577 CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181577-five 1 Tetrahydrocannabinol acts on the endocannabinoid system, which is ubiquitous in reproductive tissues Tetrahydrocannabinol, the active ingredient in marijuana, is a lipophilic compound with a prolonged half-life of 20–36 hours.1 Tetrahydrocannabinol activates the cannabinoid receptors, which are part of the endogenous endocannabinoid system. This system is found in the hypothalamus, pituitary and internal reproductive organs in both sexes.2,3 2 Marijuana use can decrease sperm count Smoking marijuana more than once weekly in the preceding 3 months (n = 130/1215) [...]
Lire la suiteThe Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ? Reilly R. Kayser, Ivar Snorrason, Margaret Haney, Francis S. Lee, and H. Blair Simpson1 Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0049 Abstract Introduction : Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments. Discussion : A growing body of basic and clinical research has showed that the endocannabinoid system(ECS) plays a role in [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suite